These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15006012)

  • 1. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
    Langley PC
    Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Clin Pharmacol; 2003; 10(4):207-10. PubMed ID: 14712327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meeting the information needs of drug purchasers: the evolution of formulary submission guidelines.
    Langley PC
    Clin Ther; 1999 Apr; 21(4):768-87; discussion 767. PubMed ID: 10363741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget.
    Zaric GS; O'brien BJ
    Health Econ; 2005 Aug; 14(8):793-803. PubMed ID: 15685669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-engineering drug development: integrating pharmacoeconomic research into the drug development process.
    Data JL; Willke RJ; Barnes JR; DiRoma PJ
    Psychopharmacol Bull; 1995; 31(1):67-73. PubMed ID: 7675991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic component of a clinical trial conducted in Latin America. Conceptual and empirical considerations.
    Reinharz D; Saldaña VR; Follador W; Asche C
    Int J Technol Assess Health Care; 2001; 17(4):571-8. PubMed ID: 11758300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
    Fry RN; Avey SG; Sullivan SD
    Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmaco-economic evaluations of new drugs: potential key to a more efficient allocation of the health care budget].
    Delwel GO; Sprenger MJ
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1068-71. PubMed ID: 12085554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of pharmacoeconomics to formulary decision making in managed care organizations.
    Suh DC; Okpara IR; Agnese WB; Toscani M
    Am J Manag Care; 2002 Feb; 8(2):161-9. PubMed ID: 11858228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
    Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
    Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.